Petrovax Pharm pick up RUIE award...
Petrovax Pharm pick up RUIE award “For the Dynamic Development of Business”
09.02.2018
Arkady Nekrasov
Founder of NPO Petrovax Pharm, Professor, Doctor of Chemistry, Winner of the State Prize of the Russian Federation.
- Company foundation.
- Registration of the Polyoxidonium® medicine and the Grippol® vaccine.
- The State Prize of the Russian Federation awarded to the team of creators and developers led by Proffessor A.V. Nekrasov for the creation of innovative medicines Polyoxidonium® and Grippol® and for their implementation in healthcare practice.
- Opening of the production facilities for manufacture of APIs, soft and solid dosage forms, and injectable forms.
- The beginning of the partnership with Solvay Pharma (currently, Abbott).
- Assignment of the International Non-proprietary Name - Azoximer bromide for Polyoxidonium® by WHO.
In 2002, a team of developers led by Professor A.V. Nekrasov was awarded the State Prize of the Russian Federation for the development and implementation of Polyoxidonium® and Grippol® into healthcare practice.
- Market launch of Longidaza®.
- Opening of a modern technological manufacturing and warehouse complex complying with GMP standards in Pokrov Village (Podolsk District, Moscow Region).
- Launch of a unique line for manufacturing medicinal products in pre-filled syringes.
- Market launch of innovative preservative-free influenza vaccine Grippol® Plus.
- Development and production of vaccines against pandemic strain of influenza A/H1N1: MonoGrippol Neo, MonoGrippol Plus, and MonoGrippol.
- Production of Grippol® Plus vaccine for the National Immunization Schedule.
- Launch of a localization project of the 13-valent conjugate pneumococcal vaccine manufacturing (in cooperation with Pfizer). The project won in the All-Russian Platinum Ounce Competition.
- The company successfully passed the EU GMP inspection.
- Acquisition of a controlling share in NPO Petrovax Pharm by Vladimir Potanin, owner and founder of the Interros Group.
- Signing agreements on the Grippol® Plus influenza vaccine localization in the Republic of Belarus and Iran.
- Market launch of the innovative Imoferaza®cosmetic cream (specialized care for scars after injury, surgery, acne).
- Assignment of the International Non-proprietary Name - bovhyaluronidase azoximer for Longidaza® by WHO.
- Obtaining official permission from the Ministry of Health of the Russian Federation for manufacture of Russian influenza vaccine – Grippol® Plus – using antigens of the influenza virus produced in Russia by Saint Petersburg Scientific Research Institute of Vaccines and Serums of the FMBA of Russia.
- The beginnig of cooperation with Boehringer Ingelheim to localize full-cycle production of innovative thrombolytic medicines “Metalyse” and “Actilyse”. Launch of the first commercial batches of Metalyse®.
- Extending the age of use of Polyoxidonium® in tablets to include children from 3 years old. Successful completion of the Post-Authorization Safety Study (PASS) of Polyoxidonium® in Europe (Slovakia).
- NPO Petrovax Pharm LLC is the winner of the All-Russian competition sponsored by the Russian Union of Industrialists and Entrepreneurs "Russian Business Leaders: Dynamics and Responsibility – 2017" in the nomination "For Dynamic Business Development".
- Completion of the clinical trials of Grippol® Quadrivalent, the first Russia’s quadrivalent inactivated subunit adjuvanted influenza vaccine. Autorization dossier submission.
- Market launch of Grippol® Quadrivalent, Russia's first quadrivalent inactivated subunit adjuvanted influenza vaccine. The Petrovax product portfolio was expanded with a new product - Velson® (international nonproprietary name: Melatonin), which helps to speed up falling asleep and improves sleep quality.
- Launch of a new 3rd line for manufacture of APIs, tablets, and suppositories. Obtaining a license and the Russian GMP certificate for a new manufacturing line. Confirming the production facilities and the Quality Management System (QMS) conformity to EU GMP rules (Slovakia). The first batches of Polyoxidonium® were supplied to Slovakia in accordance with the mandatory requirements for the labeling of medicines in the European Union.
- Victory of the Company's medicines in the 7th National Pharmaceutical Prize – Russian Pharma Awards: Polyoxidonium® in the nomination "The Medicine of Choice for Treatment and Prevention of Acute Respiratory Viral Infections and Influenza in Children"; Longidaza® in the nomination "The Medicine of Choice for Pathogenetic Therapy of Chronic Prostatitis and Relapse Prevention".
- Rebranding. The new brand identity represents the Company’s new strategy for expanding the product portfolio and intensive international integration.
- Large-scale clinical trials program for original medicinal products - Polyoxidonium® and Longidaza® - for prevention and treatment of COVID-19.
- Putting into operation the 2nd production facility for manufacturing APIs, soft and solid dosage forms. The line allowed to increase the manufacturing of APIs by 2.5 times, suppositories by 4 times and tablets by 7 times.
- Beggining of the Russian-Chinese project for the development and further production of Convidecia, a recombinant adenovirus-based viral vector vaccine for prevention of COVID-19 in cooperation with CanSino Biologics Inc. (China).
- Launch of new products:
- Uronext®, a complex remedy for urinary tract infections.
- VitaFerr®, a complex product for prevention of iron deficiency among women.
- New dosage form - Polyoxidonium® solution.
- Charity support of the Podolsk City Hospital in equipping a COVID hospital. More than 20 thousand packages of Polyoxidonium® are donated to healthcare professionals working in the “red zones” for prevention of COVID-19.
© Petrovax
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.